News
Expansion of the peptide hormone antibody portfolio
August 23 2010
Product launch: Pig NGAL ELISA Kit (KIT 044)
August 12 2010
AACC/Clinical Lab Expo 2010, July 27-29, Anaheim, CA
July 06 2010
IUTOX 2010, July 19-23, Barcelona, Spain
June 30 2010
BioPorto Diagnostics at the ERA-EDTA Congress, Munich, June 25-28
June 14 2010
BioPorto Diagnostics at APCN 2010, June 5-8, Seoul, Korea
May 21 2010
Presentation of The NGAL Test data at the BRS/RA Conference, May 17-20, Manchester, UK
May 14 2010
Product launch: new monoclonal antibodies available
May 07 2010
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
BioPorto Diagnostics obtains Quality Management Certification
February 18 2010
BioPorto Diagnostics at the World Congress of Nephrology 2009, Milan, May 22-26
May 12 2009 by Ana Belén Enfedaque Buisán
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the International Society of Nephrology (ISN) join forces once more to organize the World Congress of Nephrology 2009 connecting renal professionals from around the world in order to share insights, create new approaches to research and therapy and advance global nephrology in general.
With over 450 speakers from more than 35 countries, the congress, which will be held in Hall 5 at Fiera Milano Congressi, combines the presentation of cutting edge research with a broad overview of the currently most relevant fields in the prevention, detection and treatment of kidney disease:
• CKD – epidemiology and consequences
• Aetiology and pathogenesis of kidney disease, clinical nephrology
• Hypertension and vascular disease
• Acute kidney injury
• Renal failure and dialysis
• Transplantation
A focus product for BioPorto Diagnostics is the renal biomarker NGAL, the leading biomarker for diagnosis of acute kidney injury (AKI). The early diagnosis of AKI is important, as it is associated with a high mortallity and and up to 50% of patients in intensive care may suffer some degree of acute kidney injury. NGAL determination is also highly relevant in nephrotoxicity and kidney transplantation. The NGAL product line from BioPorto Diagnostics includes ELISA kits for research and in vitro diagnostics as well as a wide selection of reagents for use in animal models which includes antibodies against human, mouse, rat, monkey, dog NGAL and the latest new addition of antibodies against pig NGAL.
Jakob Ohm Eriksen, NGAL pharma (clinical and preclinical) Product Manager and Klaus Boberg Pedersen, Human diagnostics (NGAL and MBL) Product Manager, will welcome you at booth no. A16. For more information or setting up an appointment, please contact them at joe@bioporto.com and kbp@bioporto.com respectively. Kristian Bangert, Head of Development, kb@bioporto.com, will participate in the scientific programme.
For further information on WCN 2009: www.wcn2009.org
